vanoxerine has been researched along with Atrial Flutter in 4 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
Atrial Flutter: Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF)." | 9.22 | Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. ( Camm, AJ; Cotter, G; Davison, BA; Dittrich, HC; Feld, G; Iwashita, J; Koch, G; Kowey, PR; Piccini, JP; Pritchett, EL; van Gelder, IC; Waldo, A; Wiener, LE, 2016) |
| "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF)." | 5.22 | Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. ( Camm, AJ; Cotter, G; Davison, BA; Dittrich, HC; Feld, G; Iwashita, J; Koch, G; Kowey, PR; Piccini, JP; Pritchett, EL; van Gelder, IC; Waldo, A; Wiener, LE, 2016) |
| "Vanoxerine is a promising, new, investigational antiarrhythmic drug." | 1.37 | Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. ( Brown, AM; Cakulev, I; Khrestian, CM; Lacerda, AE; Ryu, K; Waldo, AL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dittrich, HC | 2 |
| Feld, GK | 1 |
| Bahnson, TD | 1 |
| Camm, AJ | 2 |
| Golitsyn, S | 1 |
| Katz, A | 1 |
| Koontz, JI | 1 |
| Kowey, PR | 2 |
| Waldo, AL | 3 |
| Brown, AM | 3 |
| Piccini, JP | 1 |
| Pritchett, EL | 1 |
| Davison, BA | 1 |
| Cotter, G | 1 |
| Wiener, LE | 1 |
| Koch, G | 1 |
| Feld, G | 1 |
| Waldo, A | 1 |
| van Gelder, IC | 1 |
| Iwashita, J | 1 |
| Matsumoto, N | 1 |
| Khrestian, CM | 2 |
| Ryu, K | 2 |
| Lacerda, AE | 2 |
| Cakulev, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Doses of Vanoxerine for Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm[NCT01691313] | Phase 2 | 104 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
proportion of subjects who convert to sinus rhythm through 24 hours after start of study drug (NCT01691313)
Timeframe: baseline through 24 hours
| Intervention | participants (Number) |
|---|---|
| Placebo | 10 |
| Vanoxerine 200mg | 13 |
| Vanoxerine 300mg | 16 |
| Vanoxerine 400mg | 21 |
proportion of subjects who convert to sinus rhythm through 4 hours after start of study drug (NCT01691313)
Timeframe: baseline through 4 hours
| Intervention | participants (Number) |
|---|---|
| Placebo | 4 |
| Vanoxerine 200mg | 4 |
| Vanoxerine 300mg | 11 |
| Vanoxerine 400mg | 13 |
2 trials available for vanoxerine and Atrial Flutter
| Article | Year |
|---|---|
COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Atrial Flutter; Dopamine Uptake Inhibitors; Double- | 2015 |
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blin | 2016 |
2 other studies available for vanoxerine and Atrial Flutter
| Article | Year |
|---|---|
Vanoxerine, a new drug for terminating atrial fibrillation and flutter.
Topics: Animals; Anti-Asthmatic Agents; Atrial Fibrillation; Atrial Flutter; Dogs; Electrocardiography; Hear | 2010 |
Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac | 2011 |